$JNJ

FDA approves Icotyde for psoriasis, triggering $50M payment to Protagonist. Market reacts with AbbVie stock falling 5.20% amid competitive pressure.

Global surgical stapling devices market valued at $5.47B in 2025, projected to reach $10.14B by 2035, growing 7.2% annually driven by minimally invasive procedures and obesity.

Mestag Therapeutics closes $40M financing and appoints leadership to advance FAP-targeted cancer immunotherapy MST-0312 into Phase 1 clinical trials.

Defensive sectors show conflicting technical signals: Utilities strengthen while Consumer Staples weaken and Health Care forms bearish patterns, creating mixed market outlook.

BIO-Europe Spring 2026 in Lisbon expects 3,700+ attendees, 20,000+ meetings, and robust partnering activity as global biopharma industry seeks strategic deals and investment opportunities.

SCHD offers lower costs (0.06%) and higher yield (3.4%) with 101 holdings, while HDV delivers stronger recent returns (17.6%) with 74 concentrated stocks. Choose based on cost preference and risk tolerance.

Survey of 1,100+ bladder cancer patients reveals 45% of women misdiagnosed as UTIs, 41% lack mental health support, and financial barriers limit treatment access.

Vanguard High Dividend Yield ETF gains 5% in 2026 versus S&P 500's 1.5% loss, boosted by Broadcom's 29% revenue growth and 34% net income jump driven by AI chip demand.

Two high-dividend ETFs offer similar yields but opposite strategies: FDVV embraces tech for growth; HDV favors defensive sectors for stability.

$VIG emphasizes dividend growth with 338 holdings and 1.6% yield; $HDV targets high income with 74 stocks yielding 2.9%. $VIG shows better long-term returns.

Dividend Kings Johnson & Johnson and AbbVie offer 50+ years of consecutive dividend growth with resilient pipelines successfully offsetting patent expirations.

Vanguard's $VYM offers lower fees and broader diversification with stronger recent returns, while iShares' $HDV delivers higher dividend yield through concentrated energy and defensive holdings.

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.

Global orthobiologics market projected to grow 43% to $9.52B by 2031, driven by rising osteoarthritis and regenerative therapy advancements.

$JEPI ETF generates 8%+ yields using covered call strategies, dramatically outpacing traditional dividend yields of 1-2%, though investors sacrifice capital appreciation upside.

Three dividend aristocrats—$GPC, $KMB, and $TGT—offer attractive yields and growth catalysts for income-focused investors in March 2026.

Johnson & Johnson and Zoetis identified as premier dividend stocks for income investors, citing consistent growth, innovation pipelines, and demographic tailwinds.

Seven Wall Street leaders collectively distribute $114 billion yearly to shareholders. Microsoft tops the list with $27.1 billion in dividends despite modest yield.

U.S. jobs fell 92,000 in February amid unemployment rise, geopolitical tensions, and AI concerns, triggering institutional rotation into defensive healthcare, utilities, staples, energy, and defense stocks.

FDA approves J&J's Tecvayli plus Darzalex Faspro for multiple myeloma with 83.3% three-year survival rate, expanding drug's label.